Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EADO 2018 /
Can we cure advanced metastatic melanoma patients?

6th - 9th Nov 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.11.18
Views: 793

Prof Axel Hauschild - University Hospital, Schleswig-Holstein. Germany

Prof Axel Hauschild speaks with ecancer at the EADO 2018 congress in Barcelona on whether it is possible to cure advanced metastatic melanoma patients.

Prof Hauschild explains that there is promising data for use of the PD-1 antibodies and also for the combination of ipilimumab and nivolumab.

He explains that for patients with a metastatic disease such as isolated systemic metastasis similar results or better can be achieved through surgery.

He believes that one of the remaining challenges is the development of a biomarker that is easier to use particularly on patients with a low tumour load.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation